Jasper Therapeutics, Inc.
JSPR
$5.41
$0.030.56%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 19.57% | 6.48% | 6.25% | 9.84% | 3.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.71% | 5.85% | 17.04% | 33.65% | 34.50% |
| Operating Income | -10.71% | -5.85% | -17.04% | -33.65% | -34.50% |
| Income Before Tax | -10.55% | -3.98% | -12.67% | -28.54% | -71.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.55% | -3.98% | -12.67% | -28.54% | -71.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.55% | -3.98% | -12.67% | -28.54% | -71.06% |
| EBIT | -10.71% | -5.85% | -17.04% | -33.65% | -34.50% |
| EBITDA | -10.50% | -5.46% | -17.27% | -34.15% | -34.91% |
| EPS Basic | 21.47% | 42.80% | 48.68% | 50.55% | 39.94% |
| Normalized Basic EPS | 21.27% | 42.81% | 48.83% | 50.90% | 48.02% |
| EPS Diluted | 21.47% | 42.80% | 48.68% | 50.55% | 39.94% |
| Normalized Diluted EPS | 21.27% | 42.81% | 48.83% | 50.90% | 48.02% |
| Average Basic Shares Outstanding | 39.80% | 58.29% | 86.22% | 134.30% | 185.93% |
| Average Diluted Shares Outstanding | 39.80% | 58.29% | 86.22% | 134.30% | 185.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |